Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Intra Articular Injection of Peripheral Blood Mononuclear Cells for Knee Osteoarthritis (PBMC-KOA)

8. juli 2026 opdateret af: DuoGenic StemCells Corporation (DGSC)

Peripheral-blood Cell Purification for PBMCs (PCP-PBMCs) Injection for Knee Osteoarthritis (PCP-PBMCs-KOA)

The goal of this Phase II/III, double-blinded, multicenter clinical trial is to assess the clinical efficacy of autologous peripheral blood mononuclear cells (PBMCs) in the management of knee osteoarthritis (KOA). The main questions it aims to answer are:

  1. To determine the safety of the PCP-PBMCs injection
  2. To compare the long-term efficacy between PCP-PBMCs and methylprednisolone on pain relief and motor function restoration
  3. To analyze improving quality of life after the PCP-PBMCs treatment.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

240 patients from both genders diagnosed with knee osteoarthritis, will be enrolled according to inclusion and exclusion criteria. These patients will be randomly injected with 100-200 million PBMCs, 20-60 million PBMCs or methylpredinisolone. They are then followed by clinical assessment, laboratory investigations as well as X-ray imaging of the injected knee.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

240

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

  • Taiwan
      • Chiayi City, Taiwan
        • Chang Gung Memorial Hospital, Chiayi
      • Kaohsiung City, Taiwan
        • Kaohsiung Chang Gung Memorial Hospital
      • Tainan, Taiwan
        • National Cheng Kung University Hospital
      • Taipei, Taiwan
        • National Taiwan University Hospital

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Tibiofemoral osteophytes on x-ray (Kellgren-Lawrence grade of 2-4)
  • Age ≥ 40 and ≤ 80 years.
  • Moderate to severe knee pain
  • Reduced joint space width at the medial part of the knee compared to the lateral part under x-ray examination. If standing is not feasible, the same supine position must be used consistently for follow-up.
  • A minimal pain score of 5 measured by both NRS and VAS when walking last week.
  • Knee pain on most days (no less than 15 days) in the 4 weeks before screening
  • Patients have experienced that NSAID or opioid pain medication failed to control knee pain in the last year.
  • Patients have experienced that a single intra-articular injection of medicines, such as steroids, hyaluronic acid, or platelet-rich plasma, failed to control the knee pain over 6 months.
  • Non-invasive treatments did not control the knee pain. Conservative and non-invasive treatment regimens may include any or all of the following: initial rest, muscle relaxants, massage, and oral medications, e.g., anti-inflammatory drugs, analgesics, narcotics/opioids.
  • The patients have taken supervised physical and rehabilitation therapy, such as daily walking routines, therapeutic exercises, sonication, heat/cold therapy, and electric stimulation for knee pain control within the last year.

Exclusion Criteria:

  • Patients who have taken knee, distal femur, or proximal tibia surgery.
  • Patients who took an intra-articular injection of medicine, such as steroids, hyaluronic acid, or platelet-rich plasma, in the last 3 months.
  • Reduced joint space width at the lateral part of the knee compared to the medial part under x-ray examination.
  • Patients who have severe varus deformity and tibiofemoral alignments are larger than 20 degrees.
  • Patients who cannot cooperate with the two-year follow-up.
  • Patients who have had tumor, infection, or trauma at the time of recruitment.
  • Patients with abnormal blood routine test, such as severe anemia, leukemia, sepsis, platelet dysfunction, or other blood-related diseases.
  • Patients who cannot agree to the withdrawal of non-steroid anti-inflammatory drugs (NSAIDs) or opioids during the trial period.
  • Patients who cannot cooperate with blood drawing.
  • The body mass index (BMI) value of the patient is higher than 30.
  • Female subjects who are pregnant, breastfeeding, planning to become pregnant, or unable to cooperate in contraception during the trial.
  • Subjects with a history of neurocognitive disorders, or those who have sought neurological consultation due to suspected dementia or memory decline
  • History of post-traumatic osteoarthritis.
  • History of rheumatoid arthritis, gouty arthritis, spontaneous osteonecrosis of the knee (SONK), or hemophilia.
  • Employees or family members of the PI and co-PI.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: High-dose PCP-PBMCs injection
Participants received PCP-PBMCs injection of 100-200 million PBMCs injection on day 1.
Biologisk: High-dose PCP-PBMCs injection
4 mL 100-200 million PCP-PBMCs injection into synovial cavity
Eksperimentel: Low-dose PCP-PBMCs injection
Participants received PCP-PBMCs injection of 20-60 million PBMCs injection on day 1.
Biologisk: Low-dose PCP-PBMCs injection
4 mL 20-60 million PCP-PBMCs injection into synovial cavity
Aktiv komparator: Solu-Medrol
Participants received solu-medrol solution as matching-drug on day 1.
Medicin: Solu-Medrol
4 mL solu-medrol solution, injected into synovial cavity
Andre navne:
  • Methylpredinisolone

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Reduction in Numeric Rating Scale (NRS) Score
Tidsramme: Up to 52 weeks
Mean reduction in NRS for OA pain from baseline to post-treatment. NRS is a 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) with a minimal clinically important difference (MCID) of 2.0. Participants are required to indicate a score on the scale that corresponds to their perceived level of pain in their knees.
Up to 52 weeks
Changes in scores on the Knee injury and Osteoarthritis Outcome Score (KOOS)
Tidsramme: Up to 52 weeks
The KOOS evaluates symptoms and function in subjects with knee OA, holding five separately scored subscales: Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). The KOOS ranges from 0 to 100, with lower scores indicating worse pain.
Up to 52 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Mean Reduction in Numeric Rating Scale (NRS) Score
Tidsramme: Up to 104 weeks
Mean reduction in NRS for OA pain from baseline to post-treatment. NRS is a 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) with a minimal clinically important difference (MCID) of 2.0. Participants are required to indicate a score on the scale that corresponds to their perceived level of pain in their knees.
Up to 104 weeks
Changes in scores on the Knee injury and Osteoarthritis Outcome Score (KOOS)
Tidsramme: Up to 104 weeks
The KOOS evaluates symptoms and function in subjects with knee OA, holding five separately scored subscales: Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL). The KOOS ranges from 0 to 100, with lower scores indicating worse pain.
Up to 104 weeks
Mean Reduction in the Visual Analog Scale (VAS)
Tidsramme: Up to 104 weeks

Mean reduction in VAS for osteoarthritis (OA) knee pain from baseline to post-treatment.

VAS is a 10-centimeter continuous scale ranging from 0 (no pain) to 10 (worst imaginable pain). Participants are instructed to mark a point along the line that best represents the intensity of their perceived knee pain. The distance in centimeters from the "no pain" anchor point is measured to quantify pain severity. Changes in VAS scores are used to assess treatment efficacy over time.
Up to 104 weeks
Changes in scores on the Intermittent and Constant Osteoarthritis Pain (ICOAP) questionnaire
Tidsramme: Up to 104 weeks
The ICOAP is an 11-item measure that assesses pain in individuals with knee OA, taking into account both constant and intermittent pain experiences. The ICOAP is a 5-point Likert scale, ranging from 0 to 100, with higher scores indicating worse pain.
Up to 104 weeks
Changes in scores on the Assessment of Quality of Life 8 Dimension (AQoL-8D)
Tidsramme: Up to 104 weeks
AQoL-8D consists of eight domains (independent living, happiness, mental health, coping, relationships, self-worth, pain, and senses) assessed by 35 items. AQoL-8D ranges from -0.04 to 1.00, with higher scores indicating better quality of life.
Up to 104 weeks
Change in Minimum Joint Space Width (JSW)
Tidsramme: Up to 104 weeks
JSW is commonly used to assess knee OA progression and measured by X-ray imaging. Measurement of medial JSW was facilitated by the use of automated software that delineated the femoral and tibial margins of the joint. JSW(x) was measured at 4 fixed locations. These measures of medial JSW(x) were defined as the distance from the tibial margin to the femur margin at each fixed location on the x-coordinate system. Measurement of minimum JSW was made by the software at the location of the smallest distance between the femur and tibia margins in the medial compartment.
Up to 104 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

DuoGenic StemCells Corporation (DGSC)

Samarbejdspartnere

National Taiwan University Hospital
National Cheng-Kung University Hospital
Kaoshiung Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, Chiayi

Efterforskere

  • Ledende efterforsker: Jih-Yang Ko, Chang Gung Memorial Hospital
  • Studieleder: Po-Ting Wu, National Cheng-Kung University Hospital
  • Studieleder: Chih-Hao Chang, National Taiwan University Hospital
  • Studieleder: Kuo-Chin Huang, Chang Gung Memorial Hospital, Chiayi

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. september 2026

Primær færdiggørelse (Anslået)

31. december 2028

Studieafslutning (Anslået)

31. december 2029

Datoer for studieregistrering

Først indsendt

8. juli 2026

Først indsendt, der opfyldte QC-kriterier

8. juli 2026

Først opslået (Faktiske)

14. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

8. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • PBMC-KOA

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Knæ slidgigt

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Sweden

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner